COMP <GO>
CHRW vs TMO // EV/EBITDA & P/E VALUATION
C.H. Robinson Worldwide Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CHRW 7
— TMO 6
▲ EV/EBITDA & P/E VALUATION LEADER: CHRW
LAST: $124.61 (-2.21%) • MKT CAP: $14.89B
valuation
19.5x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHRW VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHRW | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.60% | 9.30% | +13.30 | CHRW | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.5x | 30.4x | -10.90 | CHRW | /valuation <GO> |
| Free Cash Flow Yield | 6.01% | 2.40% | +3.61 | CHRW | /fcf-yield <GO> |
| Operating Margin | 4.90% | 17.40% | -12.50 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.60% | 15.10% | -11.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -8.40% | 3.90% | -12.30 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.02% | 0.24% | +1.78 | CHRW | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.42 | 4.50 | +3.92 | CHRW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.70% | +0.30 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.1 | 59.1 | -28.06 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.94 | +0.08 | CHRW | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 36.3x | -12.70 | CHRW | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.89B | $262.22B | -$247.33B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHRW REV | TMO REV | CHRW GROSS % | TMO GROSS % | CHRW FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.23B | $44.56B | 44.0% | 44.0% | $894.9M | $6.29B |
| FY 2024 | $17.72B | $42.88B | 44.0% | 44.0% | $486.4M | $7.27B |
| FY 2023 | $17.60B | $42.86B | 44.0% | 44.0% | -$59.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHRW // BETA 1.02
TMO // BETA 0.94